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Abstract
Three HIV-1-infected individuals, on virally-suppressive highly active anti-retroviral therapy (HAART), were treated in vivo with
anti-retroviral inhibitor intensification and cell stimulatory therapies in attempting to eradicate latent viral reservoirs. Afterwards, the patients
ceased all anti-retroviral drugs. Sequences of the V3 region of HIV-1 envelope protein (ENV) from patient peripheral blood mononuclear
cell (PBMC) proviral DNA, patient blood plasma viral RNA and virion-associated RNA from viruses amplified by patient cell co-culture,
were obtained before, during, and certain times after the clinical regimen. As anticipated, the V3 loop sequencing results indicate diversity
in viral strain complexity among the individual patients. However, the detection of unique V3 ENV signature sequences or V3 signatures
of low frequency, relative to those observed prior to therapy, indicate that the expression of specific viruses, or viruses of low abundance,
can be induced through stimulation in vivo. Furthermore, this stimulation or general immune activation therapy (IAT) approach, consisting
of administration of the anti-T-cell receptor antibody, OKT3, and IL-2 in vivo, appeared to have subsequently altered the genotype of the
persistent viral reservoir in peripheral blood cells for two of the three patients.
© 2003 Elsevier Inc. All rights reserved.
Keywords: HIV-1; Reservoirs; HAART; Genotype; Latency
Introduction
Human immunodeficiency virus type I (HIV-1) is a re-
markably resilient virus, in part, due to the ability of all
retroviruses, including HIV-1, to permanently integrate
their DNA into the DNA of the host cells they infect
(Kulkosky and Skalka, 1994). The integrated viral DNA is
thereafter referred to as proviral DNA or the provirus. In-
tegration links HIV-1 DNA to cell chromosomal DNA from
which production of progeny virus for the entire life span of
the cell can occur. Several potent anti-retroviral drugs have
been developed based upon intense studies of the molecular
structure of the HIV-1 enzymes, reverse transcriptase (RT)
and protease (PR) (Kohlstaedt et al., 1992; Jacobo-Molina
et al., 1993; Miller et al., 1989; Wlodawer et al., 1993).
When used in combination, these inhibitors are very effec-
tive at halting HIV-1 replication (Gulick et al., 1997),
though are unable to completely eradicate the presence of
HIV-1 leading to the establishment of a latent viral reservoir
(Wong et al., 1997). This combination therapy, referred to
as HAART, has altered the consequences of HIV-1 infec-
tion from one that had almost always led to the lethal
syndrome, AIDS, into a manageable one with a prognosis
for long-term survival (Hogg et al., 1997; Pallela et al.,
1998). However, HAART is not free of concerns, compli-
cations, or challenges (Ho, 1998; Pomerantz, 2001). Major
concerns and challenges that remain are: (1) emerging virus
in patients not adherent to therapy, (2) “break-through” of
mutant viral strains that develop resistance to HAART, (3)
inability of HAART to eradicate HIV-1 from patients de-
spite prolonged administration and finally, (4) serious side-
effects from HAART usage over time, for example, the
re-distribution of adipose tissue in patients referred to as
lipodystrophy (Carr et al., 1998, 2000).
Several fundamental questions remain associated with
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the administration of HAART. What is the identity and
relatedness of the viral strains that persist despite prolonged
administration of potent anti-HIV-1 drugs? Are these strains
sequestered within specific cells or tissue-types? Do viruses
that emerge after HAART cessation significantly re-popu-
late patients’ cells by de novo infection? Are specific vi-
ruses suppressed by therapy over time stable, turnover com-
pletely, or acquire mutations that affect their replication?
Although low-level HIV-1 replication occurs in activated
memory CD4 T-lymphocytes in both peripheral blood and
lymphoid tissues from patients on suppressive therapy, im-
portantly, the peripheral blood of these individuals also
remains populated with persistently infected, non-activated
CD4 T-lymphocytes despite HAART (Chun et al., 1997).
It is this infection of resting memory CD4 T-lymphocytes
that may largely account for the unusual longevity of per-
sistent HIV-1. In addition, some infected cell-types may
escape HAART-induced viral suppression or evade immune
clearance by residing in tissue sanctuary sites such as the
brain, testes or retina (Pomerantz, 2001). These sites are
sequestered from the peripheral blood system by endothelial
cell tight junction barriers that limit their accessibility to
compounds with anti-retroviral activity (Huisman et al.,
2000).
This report addresses many of the critical questions
raised above by identifying virus derived from peripheral
blood cells and plasma for three patients over a considerable
period of time through varying treatment regimens aimed at
viral eradication. The treatments in this translational proto-
col are unique relative to previous attempts at eradication of
persistent HIV-1 reservoirs in vivo (Kulkosky et al., 2002).
The subjects, initially on long-term virally-suppressive
HAART, were subsequently treated with additional viral
inhibitors, didanosine (ddI) and hydroxyurea (HU) to more
fully suppress viral replication. This regimen of intensifica-
tion is intended to further suppress virus replicating crypti-
cally in order to consolidate the presence of HAART-per-
sistent, latent viral species. Next the patients were subjected
to a virus/cell stimulatory protocol involving in vivo admin-
istration of interleukin II (IL-2) and a monoclonal antibody
to the CD3 T-cell receptor (OKT3) to overt expression of
persistent, residual virus. Administration of OKT3/IL-2 was
performed in the presence of HAART to block spread of
induced latent viral species. The patients subsequently had
all anti-retroviral drugs withdrawn (Kulkosky et al., 2002).
Sequence data, based upon the Variable III (V3) region,
a specific segment of the viral envelope protein (ENV)
subject to high mutability reflecting the complexity of ex-
isting viral species, reveal a diversity among patients with
regard to the dynamics of viral persistence (Milich et al.,
1993; Gunthard et al., 1999; Platt et al., 2001; Hoffman,
2002). The data also demonstrate that expression of specific
viral species or quasi-species were induced in vivo within
these patients using the stimulatory agents. It is important
that some viruses arising, either after stimulation with
OKT3/IL-2 or withdrawal of all anti-retroviral drugs
(HAART), were replication-competent while others showed
little, or at least no overt, evidence of being infectious.
Results
Identity and infectivity of HAART-persistent viral strains
Table 1 illustrates the dynamics of latent viral persis-
tence as reflected by the identity and frequency of ENV V3
sequences obtained from proviral DNA, virion-associated
RNA derived from stimulated peripheral blood mononu-
clear cells (PBMCs) in vitro or blood plasma, of patient 1
for two years. In May of 2000, patient 1 had two predom-
inant, closely related, proviral ENV V3 sequences represent-
ing 21 of 24 sequences as well as three unique variants. The
two major proviral DNA sequences differed only by a single
amino acid arginine (R) versus lysine (K) at amino acid
position 31. The majority of proviral DNA sequences indi-
cate a V3 signature at amino acid positions P13 and K32 that
are highlighted in Table 1. Just six weeks later, all V3
sequences derived from viral RNA by in vitro outgrowth of
virus, presumably originating from virus expressed after in
vivo stimulation with OKT3/IL-2, bear a variant signature
with histidine (H), R and glutamine (Q) exclusively at
positions 13, 31 and 32, respectively. Of note is the obser-
vation that V3 sequences of these viruses, amplified by
co-culture just days after in vivo OKT3/IL-2 stimulation,
bear exclusively a glycine (G) at position 25. This V3
sequence was associated with replication-competent virus
as it was derived from patient cell co-culture and represents
a unique V3 signature relative to the proviral DNA se-
quences obtained from PBMCs just 6 weeks earlier.
These observations favor the hypothesis that a latent
viral reservoir exists in this patient which could be distinct
from that within the peripheral blood compartment. Alter-
natively, it is formally possible that this infectious virus was
present at a very low frequency among other peripheral
blood proviral DNAs prior to stimulation.
Four months after OKT3/IL-2 stimulation, in October
2000, all V3 sequences from PBMC proviral DNA now bear
R exclusively at position 31 (not shaded) and Q appears
now in 7 of 8 sequences at position 32 (shaded in Table 1).
These V3 amino acids were present in only 2 of 24 proviral
DNA sequences five months earlier. It seems reasonable to
hypothesize that infectious virus, which arose after stimu-
lation with OKT3/IL-2, may have spread directly to periph-
eral blood cells and thus diluted or supplanted the major
proviral DNA species observed previously in May 2000.
Alternatively, the stimulation protocol could have induced
the clearance of a subset of cells infected with specific viral
species, thereby altering the frequencies of proviruses re-
maining after therapy, relative to those observed previously.
Of note, the “unique” V3 signature bearing the double G at
positions 24 and 25, was successfully amplified in patient
cell co-culture after in vivo OKT3/IL-2 stimulation. This
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signature was not subsequently detected in peripheral blood
cell-derived proviral DNA, patient cell viral outgrowth or
patient blood plasma from beyond October 26, 2000.
Next, blood plasma viral RNA rebounded 6 weeks after
this patient was withdrawn from all retroviral inhibitors on
January 5, 2001. Two different sequences, among seven,
were observed from this “viral burst” with one, designated
by an asterisk, bearing complete identity with that obtained
from peripheral blood cell proviral DNA 16 and 21 months
previously. The other sequence, with a plus sign, was also
observed previously in peripheral blood cell DNA after
OKT3/IL-2 stimulation and bears similarity to the viral
RNA sequences obtained immediately after stimulation
with OKT3/IL-2, but also to the sequences of minor proviral
species in PBMCs before stimulation. Interestingly, the vi-
ral RNA-derived sequence, designated with an asterisk,
emerged after HAART withdrawal without amino acid con-
version indicating persistence, relative to the “unique” sig-
nature sequence associated with viral species cultured from
the patient’s peripheral blood cells immediately following
stimulation therapy.
A full two years from the initial sequencing of viral
strains for patient 1, PBMC proviral DNA on February 12,
2002 retained R exclusively at position 31 and Q remained
predominant at position 32. H has become the most frequent
amino acid at position 13 in PBMC DNA as it had been
Table 1
Patient 1: HIV-1 V3 envelope sequences
1 10 20 30 35 Number of clones
PBMC CTRPNNNTRKSIPIGPGRAFYTTGEIIGDIRKAHC* 11 of 24
DNA CTRPNNNTRKSIPIGPGRAFYTTGEIIGDIKKAHC 10 of 24
5/4/00 CTRPNNNTRKSIPIGPGRAFYTTGEIIGDIEKAHC 1 of 24
CTRPNNNTRKSIHIGPGSAFYTTGEIIGDIRQAHCˆ 1 of 24
CTRPNNNTRKSIHIGPGSAFYTTGDIIGDIRQAHC 1 of 24
OKT3/IL-2 Administration 6/13/00
Viral CTRPNNNTRKSIHIGPGSAFYTTGGIIGDIRQAHC 9 of 11
RNA CTRPNNNTGKSIHIGPGSAFYTTGGIIGDIRQAHC 2 of 11
6/19/00a
PBMC CTRPNNNTRKSIHIGPGSAFYTTGEIIGNIRQAHC° 3 of 8
DNA CTRPNNNTRKSIHIGPGSAFYTTGEIIGDIRQAHCˆ 2 of 8
10/26/00 CTRPNNNTRKSIHIGPGSAFYTTGAIIGDIRQAHC 1 of 8
CTRPNNNTRKSIHIGPGSAFCTTGEIIGDIRQAHC 1 of 8
CTRPNNNTRKSIPIGPGRAFYTTGEIIGDIRKAHC* 1 of 8
Complete Withdrawal of HAART 1/5/01
Viral CTRPNNNTRKSIPIGPGRAFYTTGEIIGDIRKAHC* 5 of 7
RNA CTRPNNNTRKSIHIGPGSAFYTTGAIIGDIRQAHC 2 of 7
2/22/01b
Post-Study Evaluations
PBMC CTRPNNNTRKNIHIGPGSAFYTTGDIIGDIRQAHC 2 of 14
DNA CTRPNNNTRKSIHIGPGSAFYTTGDIIGDIRQAHC 2 of 14
2/12/02 CTRPNNYTRKSIHIGPGRAFYATGEIIGNTRQAHC 1 of 14
CTRPNNNTRKSIHIGPESAFYTTGAIIGDIRQAHC 1 of 14
CTRPNNNTRKSIHIGPGRTFYTT_EIIGNIRQAHC 1 of 14
CTRPNNNTKKSIHIGPGRAFYTTGEIIGDIRQAHC 1 of 14
CTRPNNNTRKSIHIRPESAFYTTGDIIGDIRQAHC 1 of 14
CTRPNNNTRKSIPIGPGKAFYTTGEIIGDIRKAHC 3 of 14
CTRPNNNTRKSIPIGPGRAFYTTGEIIGDIRKAHC* 1 of 14
CTRPNNNTRKSIPIGPGRAFYTTGEIMGDIRKAHC 1 of 14
Resting CTRPNNNTRKSIHIGPGSAFYTTGEIIGNIRQAHC° 6 of 8
T-Cell CTRPNNNTRKSIHIGPGSAFYTTGKIIGNIRQAHC 1 of 8
DNA CTRPNNNTRKSIHIGPGSAFYTTGEIMGNIRQAHC 1 of 8
4/30/02
Lab CTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHC NL4-3
Isolates CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC Bal1A
CTRPNNNTRKSINIGPGRAFYTTGEIIGDIRQAHC Bal2A
Note. *, ˆ, , °, and  indicate perfectly matched sequences.
a Viral RNA derived from virus amplified by co-culture of patient’s CD8-depleted PBMCs.
b Viral RNA derived from rebound virus in blood plasma.
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sixteen months previously unlike 5 months earlier, in May
of 2000, where H at this position was present in only in 2 of
24 proviral DNA sequences. Furthermore, the viral species
bearing the V3 sequence designated with an asterisk now is
at much lower frequency, in contrast to it being the major
species in May of 2000.
Finally, the major proviral DNA sequence, designated
with an open circle and obtained from resting CD4 T-
lymphocytes in April 2002, was isolated from PBMC DNA
in October 2000 but interestingly was not present among
sequences in PBMC proviral DNA obtained in February
2002. This indicates persistence of this viral species bearing
this specific V3 signature sequence particularly within rest-
ing CD4 T-lymphocytes.
There appeared to be near homogeneity in V3 sequences
in PBMC proviral DNA within the only cellular sample
available for this patient prior to stimulation, as shown in
Table 2. This sequence homogeneity contrasts with the
heterogeneity of V3 sequences obtained from PBMC provi-
ral DNA about 8 weeks after stimulation. There is no iden-
tical match with V3 sequences obtained prior to stimulation
relative to those determined after OKT3/IL-2 administra-
tion. It is of interest that PBMC proviral DNA, just 5
months later, then bear a uniform signature sequence of T2,
K10, E25 and N29 in 11 of 11 clones. This sequence was
observed mixed with others in the preceding proviral DNA
sample that was closer to the time of stimulation therapy.
As shown in Table 2, these eleven proviral DNA-based
sequences, designated with an asterisk, are also identical to
the majority sequence obtained from blood-borne viral
RNA that emerged after cessation of HAART. This obser-
vation suggests that this plasma viral RNA burst, after
HAART cessation, could have arisen entirely from the
PBMC proviral pool. Furthermore, there is notable persis-
tence of this viral species, designated with an asterisk, as it
remains present in the resting CD4 T-lymphocyte popu-
lation analyzed on March 2002 over a year after OKT3/IL-2
stimulation as indicated in Table 2.
Patient 3 had a pattern of viral persistence in PBMCs that
differed importantly from the initial two patients. V3 se-
quences from PBMC proviral DNA indicate two prominent
viral species on April 12, 2001, which differ from each
other at amino acid positions 10 and 29 in the V3 signature
sequences as shown in Table 3. These sequences remain in
the majority 5 months later on September 20, 2001. Al-
though this patient was treated with OKT3/IL-2 on May 1,
2001, attempts to co-culture infectious virus from peripheral
blood cells were unsuccessful 1, 3 and 7 days post-treat-
Table 2
Patient 2: HIV-1 V3 envelope sequences
1 10 20 30 35 Number of clones
PBMC DNA CIRPNNNTRRSIHIGPGRAFYATGDIIGDIRQAHC 16 of 17
10/22/99 CTRPNNNTRRSIHIGPGRAFYATGDIIGDIRQAHC 1 of 17
OKT3/IL-2 Administration (1/8/01)
PBMC DNA CTRPNNNTRKSIPIGPKRAFYATGEIIRDIRQAHC 6 of 17
3/12/01 CTRPNNNTRKSIHIGPGGAFYATGEIIRDIRQAHC 1 of 17
CTRPNNNTRKSIHIGPGRAFYATGEIIGDIRQAHC 1 of 17
CTRPYNNTRKSIHIGPGRAFYATGEIIRDIRQAHC 1 of 17
CTRPNNNTRKSIHIGPGRAFYATGEIIGNIRQAHC* 5 of 17
CTRPNNNTRKSIHIRPRRAFYATGEIIGNIRQAHC 1 of 17
CTRPNNNTRKSIPIGPKRAFYATGEIIGNIRQAHCˆ 1 of 17
CIRPNNNTRRSITIGPGRAFYATGEIIGNIRQAHC 1 of 17
PBMC DNA CTRPNNNTRKSIHIGPGRAFYATGEIIGNIRQAHC* 11 of 11
8/2/01
Complete Withdrawal of HAART (8/6/01)
Viral RNA CTRPNNNTRKSIHIGPGRAFYATGEIIGNIRQAHC* 7 of 10
9/12/01a CTRPNNYTRKSIHIGPGRAFYATGEIIGNIRQAHC 1 of 10
CTRPNNNTRKSIHIGPGRAFYATGEIIGSIRQAHC 2 of 10
Post-Study Evaluations
Resting CTRPNNNTRKSIHIGPGRAFYATGEIIGNIRQAHC* 2 of 5
T-Cell CTRPNNNTRKSIPIGPKRAFYATGEIIGNIRQAHCˆ 1 of 5
DNA CTRPSNNTRKSIHIGPGRAFYATTEQIIDIRQAHC 1 of 5
3/22/02 CTRPNNNTRKGIHIGPGRAFYATTEQIIDIRQAHC 1 of 5
Lab CTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHC NL4-3
Isolates CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC Bal1A
CTRPNNNTRKSINIGPGRAFYTTGEIIGDIRQAHC Bal2A
Note. * and ˆ indicate perfectly matched sequences.
a Viral RNA derived from rebound virus in blood plasma.
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ment. This contrasts with the subsequent successful ampli-
fication of virus by cell co-culture on January 30, 2002,
shortly following a burst of detectable virus in blood plasma
two months after HAART cessation. Interestingly, the V3
sequences derived from viral RNA after PBMC outgrowth,
subsequent to HAART cessation, indicate a prominent and
unique signature (11 of 15 clones) designated with an as-
terisk, relative to the preceding PBMC proviral DNA se-
quences. This signature bears an isoleucine (I) instead of
methionine (M) at position 14 and an R rather than G at
position 18. Two other V3 sequences are quite similar to the
asterisk virus. However, the remaining V3 sequences bear
greater similarity to that of the preceding proviral DNA
sequences than to the asterisk-denoted viral sequence.
Unlike the previous two patients, virus was successfully
co-cultured with this patient’s PBMCs after HAART ces-
sation. It would seem that the virus bearing V3 sequence
designated with the asterisk was a prime candidate for being
replication-competent. Importantly, this sequence did not
pre-exist within PBMC proviral DNA prior to cessation of
HAART but was the majority sequence from infectious
virus observed in blood plasma viral RNA after HAART
Table 3
Patient 3: HIV-1 V3 envelope sequences
1 10 20 30 35 Number of clones
PBMC CTRPSNNTRRGIHMGPGGAFYTTGQIIGNIRQAHC# 7 of 18
DNA RTRPSNNTRRGIHMGPGGAFYTTGQIIGNIRQAHC 1 of 18
4/12/01 CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIRQAHC 7 of 18
CTGPSNNTRKGIHMGPGGAFYTTGQIIGNIRQAHC 1 of 18
CTRPSNNTRKGIHIGPGRAFYTTGQIIGNIRQAHC 1 of 18
CTRPSNNTRRGIHMGPGGAFYTTGQIIGDIRQAHCˆ 1 of 18
OKT3/IL-2 Administration 5/1/01
PBMC CTRPSNNTRRGIHMGPGGAFYTTGQIIGNIRQAHC# 5 of 10
DNA CTRPSNNTRRGIHMGSGGAFYTTGQIIGNIRQAHC 1 of 10
9/20/01 CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIRQAHC 3 of 10
CTRPSNNTRKSIHMGPGGAFYTTGQIIGDIRQAHC 1 of 10
Complete Withdrawal of HAART 12/1/01
Viral CTRPSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC* 11 of 15
RNA CTRPSNNTRKGIHIGPGRAFYTTGRIIGDIRQAHC 1 of 15
1/30/02a CTRPSNNTRKGIHIGPGRAFYTTGQIVGDIRQAHC 1 of 15
CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIKQAHC 1 of 15
CTRPNNNTRKGIHMGPGGAFYTTGQIIGDIKQAHC 1 of 15
Viral CTRPSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC* 14 of 14
RNA
1/30/02b
Post-Study Evaluation
Resting CTRPSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC* 6 of 8
T-Cell CTRPSGNTRKGIHIGPGRAFYTTGQIIGDIRQAHC 1 of 8
Viral RNA CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIRQAHC 1 of 8
3/22/02c
Resting CTRPSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC* 20 of 24
T-Cell CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIRQAHC 3 of 24
DNA CTRPSNNTRKGIHMGPGRAFYTTGQIIGDIRQAHC” 1 of 24
3/22/02
PBMC CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIRQAHC 17 of 31
DNA CTRPSNNTRKGIHMGPGRAFYTTGQIIGDIRQAHC” 4 of 31
5/15/02 CTRLSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC 1 of 31
CTRPSNNTRRGIHMGPGGAFYTTGQIIGNIRQAHC# 2 of 31
CTRPSNNTRKGIHMGPGGAFYTTGQIIGNIRQAHC 1 of 31
CTRPSNNTRKGIHIGPGRAFYTTGQIIGNIRQAHC 1 of 31
CTRPSNNTRRGIHMGPGRAFYTTGQIIGDIRQAHC 2 of 31
CTRPSNNTRRGIHMGPGGAFYTTGQIIGDIRQAHCˆ 3 of 31
Note. *, #, , ”, , and ˆ indicate perfectly matched sequences.
a Viral RNA derived from virus amplified by co-culture of CD8-depleted PBMCs.
b Viral RNA derived from rebound virus in blood plasma.
c Viral RNA derived from virus outgrowth from resting CD4 T-lymphocytes. Lab isolates shown in Table 1.
621J. Kulkosky et al. / Virology 314 (2003) 617–629
removal, as indicated in Table 3. This sequence was also
observed to be prominent in viral RNA and proviral DNA
obtained from resting CD4 T-lymphocytes isolated two
months after cessation of HAART. It would appear that a
latent or low-level replicating viral pool exists in this patient
that either persists in low frequency within PBMCs or has
re-populated this compartment from another distant tissue
site and can overtly replicate in the absence of HAART.
Phylogenetic relationships of patient viral species based
on ENV V3 sequences
Rooted phylogenetic trees were constructed using the V3
sequence information from Tables 1, 2, and 3 for each
patient. The phylogenetic relationships comparing all V3
sequences over time, and through significant clinical events,
now clearly reveal heterogeneity in viral dynamics for each
patient. Importantly, the analyses also indicate whether spe-
cific groups of related, latent, viral species, or quasi-species,
exist within specific compartments for each patient. They
also define whether the clinical interventions altered their
frequency or presence within the patient via their emer-
gence, disappearance or changes in frequency within pe-
ripheral blood cells.
First, laboratory viral strains segregate away from the
patient’s V3 sequences. As shown in Fig. 1, the V3 se-
quences for laboratory strain NL4-3, numbered 73, 61 and
107 for patients 1, 2 and 3 respectively, appear on separate
branches at the bottom of Fig. 1. The macrophage-tropic
strain, BAL, numbers 74, 62, and 108 respectively, show
more relatedness to the patient’s sequences than NL4-3 but
yet no direct relation with them.
The phylogenetic tree for patient 1 reveals the most
interesting intra-patient sequence relationships. There are
two primary branches. The bottom branch segregates “ar-
chival” PBMC V3 sequences, before stimulation, with viral
RNA V3 sequences that emerge after withdrawal from
HAART. The top branch relates viral RNA from patient cell
co-culture immediately after stimulation with PBMC pro-
viral DNA also obtained after, but not before, stimulation,
as well as with resting T-lymphocyte proviral DNA se-
quenced after stimulation.
The segregation of the first branch suggests that viral
RNAs, rapidly emerging in blood plasma after HAART
cessation, are largely coming from proviral DNA templates
in peripheral blood cells. The sequences of the second large
branch seem to indicate that there could be a separate tissue
reservoir, apart from peripheral blood cells, from which
viruses are induced to express as a consequence of OKT3/
IL-2 stimulation. Alternatively, the resting T-cells may also
be a significant source from which these viral sequences
emerged. The former hypothesis is favored since the tree
shows segregation of resting T-cell sequences away from
those that appeared to be specifically induced to express by
OKT3/IL-2 treatment.
There is not such a distinct segregation of sequences for
patients 2 and 3 with regard to the effects of stimulation
therapy. The PBMC DNA sequences before and after
OKT3/IL-2 stimulation for patient 2 arise from a common
branch, though segregate into separate branches. These
groups of proviral DNA sequences are more related to each
other than the RNA-based V3 sequences that emerge in
blood plasma after HAART cessation. The plasma RNA
sequences however, do relate well with a subset of PBMC
proviral DNA sequences suggesting that most viral products
released into blood plasma are more likely originating from
peripheral blood cells of this patient. The tree for patient 3
does not appear to have distinctive features, with all se-
quences showing high relatedness one to another despite
therapeutic interventions that occurred over time.
Induction of HAART-persistent viral expression by
cellular activation
The CD8 T-lymphocyte-depleted PBMCs of the three
patients were stimulated with the activators used in vivo and
co-cultured with cells from an HIV-1 seronegative donor.
This was done since stimulation of the patient’s cells with
PHA/IL-2 might only induce selective expression of certain
latent proviruses in vitro and not others, i.e., viral species
that may have responded to OKT3/IL-2 in vivo.
As shown in Fig. 2, panels B and C, the cells of both
patients 2 and 3 successfully released and spread virus to
HIV-1-seronegative PBMC target cells when treated with
OKT3/IL-2. The cells of patient 1, similarly treated with
OKT3/IL-2, only released a small amount of virus as mea-
sured by HIV-1 p24 ELISA as indicated in panel A of Fig.
2. It is important to note the difference in scale. Importantly,
patient 1’s cells only released about 40 pgs/ml of p24
antigen during the first week of OKT3/IL-2 exposure with
no further production of virus subsequently. Two additional
attempts to induce expression of virus in this manner from
patient 1 released even lower levels of p24 antigen (data not
shown). This may be consistent with the production of
defective, or semi-defective, viruses and fits well with the
possibility that the peripheral blood cells of this specific
patient could have a diminished presence of infectious pro-
viral DNAs.
Fig. 1. Phylogenetic relationships of patient’s V3 sequences. Phylogenetic trees are shown for all patient’s V3 sequences. Sequence numbers represent the
V3 sequences taken from the respective Tables for patients 1, 2 and 3. The numbers relate to the sequences from the top of the Tables to the bottom and
account for the frequency of individual clones. For example, the first 11 sequences for patient 1, numbered 1–11 represent the PBMC DNA sequences
obtained on May 4, 2000 indicated as 11 of 24 clones. The next sequences numbered 12–21 represent the next line of sequences from May 2000 at a frequency
of 10 of 24. The numbers proceed downward in this fashion to the bottom of the Table ending with the lab isolates bearing the highest numbers. Critical
descriptive designations, relating to sequences associated with clinical interventions or time of sequence acquisition, are also provided.
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Table 4 indicates the V3 sequences of the virion-associated
RNAs obtained by cell co-culture using CD8-depleted PBMCs
of patients 2 and 3 treated in vitro with OKT3/IL-2 as de-
scribed above. The V3 sequences from viral RNA share exact
identity or are highly similar to the V3 signatures from proviral
DNA obtained previously near the date of OKT3/IL-2 stimu-
lation in vivo that were described previously in Tables 2 and 3
for these patients. This comparative data suggest that latent
viruses, associated with these V3 signature sequences, persist
within patients 2 and 3. However, viruses, seemingly induced
to express by in vivo stimulation in patient 2, were also up-
regulated for expression using the same activation treatment in
vitro. Therefore, this stimulation protocol will continue to be
used further in order to assess whether this specific virus may
decay over time within this patient.
Discussion
Three HIV-1-infected individuals were enrolled in a
novel translational, clinical protocol aimed at eradication of
latent HIV-1 reservoirs. There were no significant clinical
complications (Kulkosky et al., 2002). However, risks could
include the generation of antibodies against OKT3, a po-
tentially irreversible loss of CD4 T-lymphocytes as a
consequence of OKT3/IL-2 stimulation, as well as a decline
in CD4 T-lymphocytes associated with an increase in
peripheral blood virus that typically rebounds after HAART
withdrawal (Harrigan et al., 1999; Prins et al., 1999; Fraser
et al., 2000; van Pragg et al., 2001).
Patient 1 had a majority of PBMC V3 ENV proviral
DNA sequences that differed from subsequent viral RNA
V3 sequences within progeny virions expressed by patient
PBMC co-culture after OKT3/IL-2 stimulation in vivo. The
V3 sequences from PBMC proviral DNA, obtained after
stimulation, bore greater resemblance to the viral RNA
sequences induced by OKT3/IL-2 and had less identity to
the majority of proviral DNA sequences obtained from
PBMCs prior to stimulation. The stimulated virus, and per-
haps a related species or quasi-species, may have re-popu-
lated the peripheral blood cell pool though no HAART-
resistant mutants were detected (Kulkosky et al., 2002).
Moreover, there has been no successful culture of infectious
virus from this patient’s peripheral blood cells, only imme-
diately following stimulation therapy.
Some time after stimulation therapy, two bursts of blood
plasma virus occurred for patient 1 after cessation of
HAART at 25,000 and 15,000 RNA copies/ml of blood
plasma. It is of interest that these bursts decreased sponta-
neously without re-application of HAART (Kulkosky et al.,
2002). It would seem that these blood plasma viruses were
largely non-infectious, since multiple efforts to amplify
them by patient cell co-culture using PHA/IL-2 stimulation,
failed. Their reasonably rapid clearance or restriction may
relate, at least partially, to natural immune clearance.
Phylogenetic analyses further indicate that the burst of
plasma viral products after HAART cessation within this
patient likely emerged from within the peripheral blood
compartment itself.
V3 sequences indicate near homogeneity in “pre-ex-
isting” viral species or quasi-species several months prior
to stimulation therapy for patient 2. No viral growth
occurred by cell co-culture from PBMCs obtained imme-
diately after in vivo stimulation, although the V3 se-
quences obtained from PBMC proviral DNA after stim-
ulation were significantly more heterogeneous. Either
this, or related viruses, re-populated the peripheral blood
compartment and then became prominent, or alterna-
tively cells bearing select species were eliminated such
that complexity of the viral strains in this patient were
reduced.
Fig. 2. Induction of HAART-persistent viral expression by cellular activa-
tion. CD8 T-lymphocyte-depleted patient PBMCs were untreated (NA);
or treated with PHA/IL-2 (PHA); or OKT3/IL-2 (OKT3), then co-cultured
with CD8 T-lymphocyte-depleted PBMCs from HIV-1-seronegative do-
nors. The levels of released viral products into the cell cultures were
determined for by detection of HIV-1 p24 antigen each week, for at least
three weeks, by ELISA.
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Amplification of infectious virus was successful by cell
co-culture of patient 2’s PBMCs prior to in vivo stimulation
therapy but several additional attempts through the period of
intensification, stimulation and cessation of HAART failed.
Nonetheless, this patient’s cells robustly released replication-
competent virus after stimulation in vitro with OKT3/IL-2.
The first positive co-culture occurred for Patient 3 about
six weeks after cessation of HAART and was coincident
with a spike of 22,000 copies/ml of viral RNA in blood
plasma (Kulkosky et al., 2002). This patient, unlike the first
two, exhibited overt evidence of a replication-competent
latent viral reservoir relatively rapidly after cessation of
HAART.
There is likely no simple paradigm that can be uniformly
applied with regard to the existence, location and stability of
latent HIV-1 reservoirs for the majority of HIV-1-infected
individuals on virally-suppressive HAART (Garcia et al.,
1999; Ioannidis et al., 2000; Harrold et al., 2002; Chun et
al., 1998, 2002). Several reports indicate that virus, which
rapidly spikes in blood plasma after cessation of HAART,
could be derived from proviral DNA within resting memory
CD4 T-lymphocytes (Finzi et al., 1999; Blaak et al., 2000;
Karlsson et al., 2001; Douek et al., 2002). It also seems
reasonable to initially question whether the major V3 se-
quences found in resting CD4 T-lymphocytes of patients
1 and 2 were associated with a replication-competent vi-
ruses indicated in Tables 1 and 2 with a circle and asterisk
respectively. In the final studies including patient 2, in vitro
stimulation with OKT3/IL-2 released infectious virus from
this patient’s CD8-depleted peripheral blood cells that
matched the V3 signature within the resting T-cell popula-
tion of this patient. Patient 3 of our study, on the other hand,
bears a predominant V3 sequence in both resting CD4
T-lymphocyte viral RNA and DNA, which was also ob-
served in PBMC out-growth viral RNA after cessation of
HAART. This V3 signature, designated with an asterisk,
was also associated with viruses amplified by OKT3/IL-2
stimulation in vitro. This patient therefore exhibits a pattern
of latent viral persistence with similar species being de-
tected essentially throughout the course of this study.
Some viruses may spontaneously emerge from viral res-
ervoirs within patients where suppression of on-going viral
Table 4
Comparison of V3 envelope sequences associated with OKT3/IL-2 stimulation in vivo and in vitro
Patient 2: V3 Env Sequences
OKT3/IL-2 Administration (1/8/01) in vivo
PBMC DNA CTRPNNNTRKSIPIGPKRAFYATGEIIRDIRQAHCˆ 6 of 17
3/12/01a CTRPNNNTRKSIHIGPGRAFYATGEIIGNIRQAHC* 5 of 17
OKT3/IL-2 Stimulation (6/12/02) in vitro
Viral CTRPNNNTRKSIPIGPKRAFYATGEIIRDIRQAHCˆ 3 of 7
RNA CTRPNNNTRKSIPIGPGRAFYATGEIIGDIRQAHC 1 of 7
CTRPNNNTRKSMPIGPKRAFYATGEIIGDIRQAHC 1 of 7
CTRPNNNTRKSIHIRPGRAFYATGEIIRNIRQAHC 1 of 7
CTRPNNNTRKSIHIGPGRAFYATGEIIGNIRQAHC* 1 of 7
Note. * and ˆ indicate perfectly matched sequences.
a Sequence taken from Table 3.
Patient 3: V3 Env Sequences
OKT3/IL-2 Administration 5/1/01 in vivo
PBMC CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIRQAHC 3 of 10
DNA CTRPSNNTRKSIHMGPGGAFYTTGQIIGDIRQAHC 1 of 10
9/20/01a CTRPSNNTRRGIHMGPGGAFYTTGQIIGNIRQAHC# 5 of 10
CTRPSNNTRRGIHMGSGGAFYTTGQIIGNIRQAHC 1 of 10
Complete Withdrawal of HAART 12/1/01
Viral CTRPSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC* 11 of 15
RNA CTRPSNNTRKGIHIGPGRAFYTTGRIIGDIRQAHC 1 of 15
1/30/02a CTRPSNNTRKGIHIGPGRAFYTTGQIVGDIRQAHC 1 of 15
CTRPSNNTRKGIHMGPGGAFYTTGQIIGDIKQAHC 1 of 15
CTRPNNNTRKGIHMGPGGAFYTTGQIIGDIKQAHC 1 of 15
OKT3/IL-2 Stimulation (6/12/02) in vitro
Viral CTRPSNNTRKGIHIGPGRAFYTTGQIIGDIRQAHC* 6 of 7
RNA CTRPSNNTRKGIHIGPGRAFYTTGQVIGDIRQAHC 1 of 7
Note. * indicates perfectly matched sequences.
a Sequences taken from Tables 2 and 3.
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replication by HAART is incomplete. For patients where
complete suppression has occurred, virus expression upon
HAART removal may indeed emerge from a latent reser-
voir, the source of which remains to be identified. These
conclusions were based on the genetic characterization of
rebounding virus from 8 patients after cessation of HAART
(Zhang et al., 2000). Interestingly, significant spikes in
plasma viral load occurred from what appears to be a sin-
gular virus, without CD4 T-lymphocyte loss, in some
patients within this study. We suspect that if the majority of
virus were infectious, a greater decrease in CD4 T-lym-
phocytes might have been expected to occur.
Another investigation of nine patients noted that re-
bounding viruses, emerging after cessation of HAART, had
a distinct phenotype apart from that detected within resting
peripheral blood CD4 T-lymphocytes for most patients
(Chun et al., 2001). Of interest in this report was a measure
of blood plasma copy number after HAART cessation in
conjunction with a determination of viral infectious units
from resting CD4 T lymphocytes. Importantly, one pa-
tient had no change in viral infectious units, which was
gauged to be less than 2 units per million CD4 resting
T-lymphocytes, despite a blood plasma RNA copy number
of 50 per milliliter that spiked to several hundred thou-
sand copies after HAART cessation. The release of such a
large amount of virus without apparent effect in an infec-
tivity assay may indicate the viruses were largely non-
infectious.
A study of three patients found that HIV-1 quasi-species,
which rebounded after removal of HAART, were similar to
the viral sequences present before HAART was initiated.
Indeed, there may be persistent pool of replicating virus in
certain patients that does not require activation from a
previously latent pool, as this report suggests (Imamichi et
al., 2001).
Patient 1 in our study appeared to have a pool of virus
that expressed due to in vivo activation with OKT3/IL-2 and
was clearly replication-competent as demonstrated by suc-
cessful co-culturing of virus. We favor the hypothesis that
this virus emerged from a unique cellular compartment
distinct from PBMCs, but perhaps resting CD4 T-lym-
phocytes, or other possibilities such as monocytes or tissue-
bound macrophages (Zhu et al., 2001). The data for patient
1 also suggest that these infectious viruses were likely being
restricted for expression over time, as viral amplification via
co-culture was successful only within a narrow time frame
after stimulation in vivo. Furthermore, multiple attempts to
deliberately induce expression of HAART-persistent virus
from PBMCs by stimulation with OKT3/IL-2 in vitro failed
for patient 1 but were successful for both patients 2 and 3.
Viral products in blood plasma most likely originated from
peripheral blood cells.
There is evidence that most virus particles released from
infected patient’s cells are not replication-competent and
some can be derived directly from defective proviral DNAs
(Sanchez et al., 1997). The analyses of patient 1 presented
here, coupled with events observed with the previous study
(Kulkosky et al., 2002), indicate this may be the case for the
majority of viral products released from the peripheral
blood cells of patient 1. There may be many mechanisms
that could be involved in reducing the burden of replication-
competent viruses within patients including recombination
with defective viral sequences. This can occur when com-
petent and defective viral RNAs are co-packaged into viri-
ons that then generate non-infectious virions after reverse
transcription (Sanchez et al., 1997; Janini et al., 2001;
Belmonte et al., 2002).
In summary, it appears reasonable to propose that some
patients, on HAART for prolonged periods, may bear min-
imal vestiges of infectious or replication-competent virus, at
least in the peripheral blood cell compartment, as may be
the case for patient 1 of our study. This is consistent with
what appears to be a latter, perhaps final phase of viral
decay, in certain patients on virally-suppressive HAART
based upon mathematical modeling, which we have dem-
onstrated recently on a separate patient cohort (Mascio et
al., 2003). The study further demonstrates that in vivo in-
tervention with stimulatory agents can directly alter or per-
turb HIV-1 reservoirs in vivo, as detected by differences in
viral species populating the peripheral blood compartment.
Such alterations, as detected in this study, leave open the
possibility that interdiction in HIV-1 residual disease via
stimulation or immune activation therapy (IAT), which em-
ploys cellular mitogens or cellular activators, may yet be a
viable clinical option (Kulkosky and Pomerantz, 2002).
Methods
Clinical protocol
The details of the viral intensification and stimulation
clinical protocol in patients utilizing didanosine/hydroxy-
urea plus OKT3/IL-2, and methods for detecting the plasma
viral RNA copy number after clinical intervention as well as
the subsequent results were published previously (Kulkosky
et al., 2002). Each patient in this study signed an Institu-
tional Review Board-approved consent form.
CD8-depleted PBMC co-culture assay
CD8 T-lymphocytes were depleted from PBMCs de-
rived from Histopaque (Sigma, St. Louis, MO, USA) sep-
aration by binding to magnetic beads conjugated with the
anti-CD8 antibody (CD8 Dynabeads from Dynal, Oslo,
Norway). Partial removal of monocytes was next accom-
plished by incubation of the CD8-depleted T-lymphocytes
overnight in T-75 plastic culture flasks (Becton Dickinson,
Franklin Lakes, NJ, USA) The remaining non-adherent pa-
tient-derived peripheral blood lymphocytes (PBLs) were
then stimulated with 5 gs/ml of phytohemagglutinin
(PHA) obtained from Sigma, St. Louis, MO, and 50
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Units/ml of IL-2 from, USA Gibco-BRL, Grand Island, NY,
USA. PBLs were isolated from HIV-1-seronegative donors
using the same procedure. In latter experiments, patient
cells were stimulated with 5 ugs/ml PHA or 1 ug/ml of
OKT3 with IL-2, at the concentration denoted above. CD8-
depleted PBLs (5–10  106) from the HIV-1-infected pa-
tients were then mixed with those from HIV-1-seronegative
donors (2  106 cells each) and cultured in T25 culture
flasks using RPMI-1640 medium with 10% fetal calf serum
(FCS) and penicillin/streptomycin at 37°C for 6 to 8 weeks.
Twice a week, half of the media was replaced with fresh
media and once a week, half the cells were replaced with 2
 106 fresh PBLs from HIV-1-seronegative donors after
they were CD8 T-lymphocyte depleted and stimulated
with PHA/IL-2 as described above. Media isolated after
feeding of the co-cultures each week were screened for the
presence of HIV-1 p24 antigen by an enzyme-linked immu-
nosorbent assay (ELISA) from Dupont, Wilmington, DE,
USA.
Resting CD4 T-lymphocyte isolation
Resting CD4 T-lymphocytes were isolated using a
Miltenyi automated cell isolation device. For this, patient
PBMCs, purified by Histopaque separation, were first se-
lected to remove cells bearing the CD8, CD14, CD19, and
CD16 cell surface markers using microbeads conjugated
with antibodies for these respective surface markers and
obtained from Miltenyi Inc., Auburn, CA, USA. The neg-
ative fraction, obtained after the selection above, was then
conjugated with CD69, CD25 and HLA-DR antibodies. The
negative fraction of cells from this selection was washed as
recommended by the manufacturer and then positively se-
lected for the presence of CD4 resulting in the capture of
CD4, HLA-DR, resting T-lymphocytes.
HIV-1 gp120 ENV V3 loop sequencing and phylogenetic
analysis
The sequences for the V3 region of HIV-1 ENV were
obtained from polymerase chain reaction (PCR) products of
this region which were then inserted into the bacterial vec-
tor, pUC19. V3 inserts were amplified by nested PCR, first
after cDNA synthesis from viral RNA using Superscript II
RT (Gibco-BRL) and the external primer, KK4043. The
first PCR amplification from viral cDNA or from proviral
DNA (1 ug of template), extracted from patients’ cells, used
the external primers, KK30 and KK40, as described previ-
ously (Zhang et al., 1998). A portion of this reaction was
then subjected to a second round of PCR amplification using
the internal primer set as reported (Zhang et al., 1998),
except this primer set was modified so that the KK10 and
KK20 primers bear 5 EcoR1 and Pst1 sites, respectively.
This modification permits unidirectional cloning into
pUC19 after this vector was digested with EcoR1 and Pst1.
The ligated DNAs were transformed into competent DH5-
cells (Gibco-BRL) and plated on LBBA plates containing
200 g/ml of X-gal and IPTG (both reagents from Gibco-
BRL). Plasmid DNAs, purified from overnight growth of
white or very light blue colonies, were isolated using the
mini-prep DNA isolation kit from Qiagen, Valencia, CA,
USA, then digested with EcoR1 and Pst1 to identify vectors
bearing the V3 insert. There was no visible digestion into
smaller fragments of the patient V3 PCR products after
separation on 1.5% agarose gel providing reasonable con-
fidence that these small 220 base-pair templates were de-
void of EcoR1 and Pst1 recognition sites. The positive
clonal DNA was then analyzed using the M13 sequencing
primer with an automated sequencer (Prism model 377 with
XL Upgrade, Perkin-Elmer Applied Biosystems, Foster
City, CA, USA) Multiple independent clones were se-
quenced. Sequence contaminants were ruled out by com-
parison of obtained sequences with common laboratory vi-
ral isolates and BLAST searches using the Genbank
sequence database.
Phylogenetic trees of patient-based V3 sequences were
created using Lasergene sequence analysis software ob-
tained from DNASTAR Inc., Madison, WI, USA. The
MegaAlign function of the software was used to generate
multiple sequence alignments. The MegaAlign function has
a phylogenetic tree palette tool to create rooted DNA-based
sequence trees. The straight branch palette tool was em-
ployed for generating the phylogenetic trees. This analysis
software is based on the original public versions of the
ClustalV and ClustalW alignment programs. The patient
DNA-based sequences have been submitted to GenBank with
the following accession numbers: patient 1  AY305404–
AY305423; patient 2  AY305424–AY305439; patient 3
 AY305440–AY305457. Perfectly matched DNA-based
sequences, within each patient grouping, were not reiterated
in the submission.
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